Discover

'Leishmaniasis' is a disease caused by protozoan parasites that belong to the genus ''Leishmania'' and is transmitted by the bite of certain species of sand fly, including flies in the genus ''Lutzomyia'' in the New World and ''Phlebotomus'' in the Old World. The disease was named in 1901 for the Scottish pathologist William Boog Leishman. This disease is also known as Leichmaniosis, Leishmaniose, leishmaniose, and formerly, 'Orient Boils', 'kala azar', 'black fever', 'sandfly disease', 'Dum-Dum fever' or 'espundia'.
Most forms of the disease are transmissible only from animals (zoonosis), but some can be spread between humans. Human infection is caused by about 21 of 30 species that infect mammals. These include the ''L. donovani'' complex with three species (''L. donovani, L. infantum'', and'' L. chagasi''); the ''L. mexicana'' complex with 3 main species (''L. mexicana, L. amazonensis'', and ''L. venezuelensis''); ''L. tropica; L. major; L. aethiopica''; and the subgenus ''Viannia'' with four main species (''L. (V.) braziliensis, L. (V.) guyanensis, L. (V.) panamensis'', and ''L. (V.) peruviana''). The different species are morphologically indistinguishable, but they can be differentiated by isoenzyme analysis, DNA sequence analysis, or monoclonal antibodies.
Visceral leishmaniasis is a severe form in which the parasites have migrated to the vital organs.

Contents

Geography and epidemiology

Life cycle

Signs and symptoms

Treatment

History

Leishmaniosis as part of the CVBDs

See also

References

External links

Geography and epidemiology

Leishmaniasis can be transmitted in many tropical and sub-tropical countries, and is found in parts of about 88 countries. Approximately 350 million people live in these areas. The settings in which leishmaniasis is found range from rainforests in Central and South America to deserts in West Asia. More than 90 percent of the world's cases of visceral leishmaniasis are in India, Bangladesh, Nepal, Sudan, and Brazil.
Leishmaniasis is also found in Mexico, Central America, and South America—from northern Argentina to southern Texas (not in Uruguay, Chile, or Canada), southern Europe (leishmaniasis is not common in travelers to southern Europe), Asia (not Southeast Asia), the Middle East, and Africa (particularly East and North Africa, with some cases elsewhere). The disease is not found in Australia or Oceania.
Leishmaniasis is present in Iraq and was contracted by a number of the troops involved in the 2003 invasion of that country and the subsequent occupation. The soldiers nicknamed the disease the 'Baghdad boil'. It has been reported by Agence France-Presse that more than 650 U.S. soldiers may have experienced the disease between the start of the invasion in March 2003 and late 2004. [1]
[2]
In fact, U.S. troops have experienced leishmaniasis cases in the Middle East already previously to the 2003 invasion, during the time of the previous Gulf conflict, when a large number of soldiers were stationed in Saudi Arabia. Of the 32 cases that were recorded by the U.S. military for that period (1990-1991), 20 were cutaneous, and 12 of the more severe visceral type [www.pdhealth.mil/downloads/Leishmaniasis_exsu_16Mar042.pdf].
During 2004, it is calculated that some 3,400 troops from the Colombian army, operating in the jungles near the south of the country (in particular around the Meta and Guaviare departments), were infected with Leishmaniasis. Apparently, a contributing factor was that many of the affected soldiers did not use the officially provided insect repellent, because of its allegedly disturbing odor. It is estimated that nearly 13,000 cases of the disease were recorded in all of Colombia throughout 2004, and about 360 new instances of the disease among soldiers had been reported in February 2005. [3]
[4]
[5]
In September 2005 the disease was contracted by at least four Dutch marines who were stationed in Mazari Sharif, Afghanistan, and subsequently repatriated for treatment.
Within Afghanistan, in particular Kabul is a town where leishmaniasis occurs commonly - partly to do with bad sanitation and waste left uncollected in streets, allowing parasite-spreading sand flies an environment they find favorable. See e.g. [6] and [7]. In Kabul the number of people infected is estimated at at least 200,000, and in three other towns (Herat, Kandahar and Mazar-i-Sharif) there may be about 70,000 more, according to WHO figures from 2002 cited e.g. here: [8].

Life cycle

Leishmaniasis is transmitted by the bite of female phlebotomine sandflies. The sandflies inject the infective stage, metacyclic promastigotes, during blood meals '(1)'. Metacyclic promastigotes that reach the puncture wound are phagocytized by macrophages '(2)' and transform into amastigotes '(3)'. Amastigotes multiply in infected cells and affect different tissues, depending in part on which ''Leishmania'' species is involved '(4)'. These differing tissue specificities cause the differing clinical manifestations of the various forms of leishmaniasis. Sandflies become infected during blood meals on an infected host when they ingest macrophages infected with amastigotes '(5,6)'. In the sandfly's midgut, the parasites differentiate into promastigotes '(7)', which multiply, differentiate into metacyclic promastigotes and migrate to the proboscis '(8)

Signs and symptoms

The symptoms of leishmaniasis are skin sores which erupt weeks to months after the person affected is bitten by sand flies. Other consequences, which can become manifest anywhere from a few months to years after infection, include fever, damage to the spleen and liver, and anaemia.
In the medical field, leishmaniasis is one of the famous causes of a markedly enlarged spleen, which may become larger even than the liver. There are four main forms of leishmaniasis:

★ Visceral leishmaniasis - the most serious form and potentially fatal if untreated.

★ Cutaneous leishmaniasis - the most common form which causes a sore at the bite site, which heal in a few months to a year, leaving an unpleasant looking scar. This form can progress to any of the other three forms.

★ Diffuse cutaneous leishmaniasis - this form produces widespread skin lesions which resemble leprosy and is particularly difficult to treat.

★ Mucocutaneous leishmaniasis - commences with skin ulcers which spread causing tissue damage to (particularly) nose and mouth

Treatment

There are two common therapies containing antimony (known as pentavalent antimonials), meglumine antimoniate (''Glucantim''®) and sodium stibogluconate (''Pentostam''®). It is not completely understood how these drugs act against the parasite; they may disrupt its energy production or trypanothione metabolism. Unfortunately, in many parts of the world, the parasite has become resistant to antimony and for visceral or mucocutaneous leishmaniasis,^[1] but the level of resistance varies according to species.^[2] Amphotericin is now the treatment of choice^[3]; failure of AmBisome® to treat visceral leishmaniasis (''Leishmania donovani'') has been reported in Sudan,^[4] but this failure may be related to host factors such as co-infection with HIV or tuberculosis rather than parasite resistance.
Miltefosine (Impavido®), is a new drug for visceral and cutaneous leishmaniasis. The cure rate of miltefosine in phase III clinical trials is 95%; Studies in Ethiopia show that is also effective in Africa. In HIV immunosuppressed people who are coinfected with leishmaniasis it has shown that even in resistant cases 2/3 of the people responded to this new treatment. Clinical trials in Colombia showed a high efficacy for cutaneous leishmaniasis. In mucocutaneous cases caused by L.brasiliensis it has shown to be more effective than other drugs.
Miltefosine received approval by the Indian regulatory authorities in 2002 and in Germany in 2004. In 2005 it received the first approval for cutaneous leishmaniasis in Colombia. Miltefosine is also currently being investigated as treatment for mucocutaneous leishmaniasis caused by ''L. braziliensis'' in Colombia, and preliminary results are very promising. It is now registered in many countries and is the first orally administered breakthrough therapy for visceral and cutaneous leishmaniasis.^[5](More, ''et al'', 2003). In October 2006 it received orphan drug status from the US Food and Drug administration.
The drug is generally better tolerated than other drugs. Main side effects are gastrointetinal disturbance in the 1-2 days of treatment which does not affect the efficacy. Because it is available as an oral formulation, the expense and inconvenience of hospitalisation is avoided, which makes it an attractive alternative.
The Institute for OneWorld Health has developed paromomycin, results with which led to its approval as an orphan drug. The Drugs for Neglected Diseases Initiative is also actively facilitating the search for novel therapeutics.
Drug-resistant leishmaniasis may respond to immunotherapy (inoculation with parasite antigens plus an adjuvant) which aims to stimulate the body's own immune system to kill the parasite.^[6]
Several potential vaccines are being developed, under pressure from the World Health Organization, but as of 2006 none is available. The team at the Laboratory for Organic Chemistry at the Swiss Federal Institute of Technology (ETH) in Zürich are trying to design a carbohydrate-based vaccine [9]. The genome of the parasite ''Leishmania major'' has been sequenced,^[7] possibly allowing for identification of proteins that are used by the pathogen but not by humans; these proteins are potential targets for drug treatments.

History

Description of conspicuous lesions similar to cutaneous Leishmaniasis (CL) has been discovered on tablets from King Ashurbanipal from the 7th century BCE, some of which may have been derived from even earlier texts from 1500 to 2500 BCE. Arab physicians including Avicenna in the 10th century gave detailed description of what was called Balkh sore^[8]. In 1756, Alexander Russell, after examining a Turkish patient, gave one of the most detailed clinical description of the disease. Physicians in the Indian Subcontinent would describe it as Kala-azar (pronounced ''kālā āzār'', the Urdu, Hindi and Hindustani phrase for ''black fever'', ''kālā'' meaning black and ''āzār'' meaning fever or disease). As for the new world, evidence of cutaneous form of the disease was found in Ecuador and Peru in pre-Inca potteries depicting skin lesions and deformed faces dating back to the first century CE. 15th and 16th century texts from Inca period and from spanish colonials mention ''"valley sickness"'', ''"Andean sickness"'' or ''"white leprosy"'' which are likely to be CL.
Who first discovered the organism is somewhat disputed. It is possible that Surgeon major Cunnigham of British Indian army saw it first in 1885 without being able to relate it to the disease^[9][10]. In 1901, Leishman identified certain organisms in smears taken from the spleen of a patient who had died from "dum-dum fever" (Dhum dhum is an area close to Calcutta) and in 1903 Captain Charles Donovan (1863-1951) described them as being new organism^[11]. Eventually Ronald Ross established the link with the disease and named the organism ''Leishmania donovani''.

Leishmaniosis as part of the CVBDs

CVBD stands for Canine Vector-borne diseases, which are diseases transmitted through Ectoparasites.

See also

★ Visceral leishmaniasis (kala azar)

★ Cutaneous leishmaniasis

★ Leishmania

References

1. Oral miltefosine to treat new world cutaneous leishmaniasis, Soto J, Toledo JT., , , Lancet Infect Dis,
2. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis, Arevalo J, Ramirez L, Adaui V,''et al.'', , , J Infect Dis, 2007
3. Amphotericin B Treatment for Indian Visceral Leishmaniasis: Response to 15 Daily versus Alternate-Day Infusions, Sundar S, Chakravarty J, Rai VK, ''et al.'', , , Clin Infect Dis, 2007
4. Unresponsiveness to AmBisome® in some Sudanese patients with kala-azar, Mueller M, Ritmeijer K, Balasegaram M, Koummuki Y, Santana MR, Davidson R., , , Trans R Soc Trop Med Hyg, 2007
5. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis, Jha TK, Sundar S, Thakur CP ''et al.'', , , New Engl J Med, 1999
6. Immunotherapy for drug-refractory mucosal leishmaniasis, Immunotherapy for Drug-Refractory Mucosal Leishmaniasis, , , J Infect Dis, 2006
7. The genome of the kinetoplastid parasite, Leishmania major, Ivens AC, ''et al.'', , , Science, 2005
8. The Wellcome Trust illustrated history of tropical diseases, , Francis E G, Cox, The Wellcome Trust, ,
9. On the presence of peculiar parasitic organisms in the tissue of a specimen of Delhi boil, , DD, Cunningham, Printed by the superintendent of government printing, India, 1885,
10. History of human parasitology, Cox FE, , , Clin. Microbiol. Rev., 2002
11. WHO: Leishmaniasis: background information

External links

★ Doctors Without Borders' leishmaniasis information page

★ Drugs for Neglected Diseases Initiative

★ International Leishmania Network

★ Leish-L discussion list

★ Wanted: social entrepreneurs Nature 434, 941 (21 April 2005)

★ Symposium issue, , , , Journal of Postgraduate Medicine, 2003

★ Open Directory Project - ''Leishmaniasis'' directory category